Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
103 studies found for:    autoinflammatory
Show Display Options
Rank Status Study
21 Completed The Rifaximin Study in CVID
Condition: Common Variable Immunodeficiency (CVID)
Intervention: Drug: Rifaximin
22 Recruiting Life Quality Study for PFAPA Patient
Condition: PFAPA Syndrome
Intervention: Other: Quality of life
23 Active, not recruiting Ilaris® Effects in Schnitzler Syndrome (ILESCH)
Condition: Schnitzler Syndrome
Interventions: Drug: Canakinumab;   Drug: Placebo
24 Completed AnakInRa for Treatment of Recurrent Idiopathic Pericarditis (AIRTRIP)
Condition: Idiopathic Recurrent Pericarditis
Interventions: Drug: Anakinra;   Drug: Placebo
25 Completed Rilonacept for Deficiency of the Interleukin-1 Receptor Antagonist (DIRA)
Condition: DIRA
Intervention: Drug: Rilonacept
26 Completed the Influence of Remote Ischemic Preconditioning on Inflammation During Human Endotoxemia
Conditions: Autoimmune Diseases;   Infection
Interventions: Other: Multiple-dose Remote Ischemic Preconditioning;   Other: Single-dose Remote Ischemic Preconditioning;   Biological: LPS infusion
27 Completed Efficacy and Safety of Canakinumab in Schnitzler Syndrome
Condition: Schnitzler Syndrome
Intervention: Drug: Canakinumab
28 Recruiting Anakinra for Inflammatory Pustular Skin Diseases
Condition: Pustular Dermatosis
Intervention: Drug: Anakinra
29 Recruiting Cold Contact Urticaria Treatment With Rilonacept
Condition: Cold Contact Urticaria
Interventions: Drug: Rilonacept;   Drug: Placebo
30 Completed Canakinumab for Pyoderma Gangrenosum
Condition: Pyoderma Gangrenosum
Intervention: Drug: Canakinumab
31 Recruiting HL2351 CAPS Phase II Study
Condition: Cryopyrin‑Associated Periodic Syndromes (CAPS)
Intervention: Drug: HL2351
32 Completed
Has Results
Efficacy, Safety, and Tolerability of ACZ885 in Patients With Muckle-Wells Syndrome
Condition: Muckle Wells Syndrome
Interventions: Drug: ACZ885;   Drug: Placebo
33 Completed
Has Results
Rilonacept for Treatment of Familial Mediterranean Fever (FMF)
Condition: Familial Mediterranean Fever
Interventions: Drug: Rilonacept;   Drug: Placebo
34 Recruiting Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Conditions: Other Specified Inflammatory Disorders of Skin or Subcutaneous Tissue;   Pyoderma Gangrenosum;   Erosive Pustular Dermatosis of the Scalp;   Sweet's Syndrome;   Behcet's Disease;   Bowel-associated Dermatosis-arthritis Syndrome;   Pustular Psoriasis;   Acute Generalized Exanthematous Pustulosis;   Keratoderma Blenorrhagicum;   Sneddon-Wilkinson Disease;   IgA Pemphigus;   Amicrobial Pustulosis of the Folds;   Infantile Acropustulosis;   Transient Neonatal Pustulosis;   Neutrophilic Eccrine Hidradenitis;   Rheumatoid Neutrophilic Dermatitis;   Neutrophilic Urticaria;   Still's Disease;   Erythema Marginatum;   Unclassified Periodic Fever Syndromes / Autoinflammatory Syndromes;   Dermatitis Herpetiformis;   Linear IgA Bullous Dermatosis;   Bullous Systemic Lupus Erythematosus;   Inflammatory Epidermolysis Bullosa Aquisita;   Neutrophilic Dermatosis of the Dorsal Hands (Pustular Vasculitis);   Small Vessel Vasculitis Including Urticarial Vasculitis;   Erythema Elevatum Diutinum;   Medium Vessel Vasculitis
Intervention: Procedure: Collection of biological samples
35 Completed
Has Results
Efficacy and Safety Study of ACZ885 in Patients With Active Recurrent or Chronic TNF-receptor Associated Periodic Syndrome (TRAPS).
Condition: TNF-receptor Associated Periodic Syndromes (TRAPS)
Intervention: Drug: ACZ885
36 Enrolling by invitation Heat Intolerance in the Group of FMF Patients
Conditions: Familial Mediterranean Fever;   Heat Intolerance;   Heat Tolerance Test
Intervention:
37 Completed The Safety and Efficacy of Canakinumab in Patients Aged 4 Years or Older Diagnosed With Cryopyrin-associated Periodic Syndromes (CAPS) in Canada
Condition: Cryopyrin Associated Periodic Syndrome
Intervention: Drug: canakinumab (company code: ACZ885D)
38 Not yet recruiting An Extention Study of Safety of Canakinumab in Japanese Patients With Periodic Fever Syndromes
Condition: Periodic Fevers Syndrome
Intervention: Biological: canakinumab
39 Completed Clinical Outcomes and Safety: A Registry Study of Ilaris (Canakinumab) Patients
Conditions: Cryopyrin-associated Periodic Syndromes (CAPS);   Familial Cold Autoinflam Syn (FCAS);   Muckle-wells Syn (MWS);   Neonatal Onset Multisystem Inflam Disease (NOMID)
Intervention:
40 Completed The CARRA Registry
Conditions: Juvenile Idiopathic Arthritis;   Systemic Lupus Erythematosus;   Mixed Connective Tissue Disease;   Juvenile Ankylosing Spondylitis;   Juvenile Dermatomyositis;   Localized Scleroderma;   Systemic Sclerosis;   Vasculitis;   Sarcoid;   Fibromyalgia, Primary;   Auto-inflammatory Disease;   Idiopathic Uveitis Idiopathic
Intervention:

First Page    Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.